Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Craig Rayner"'
Autor:
Beesan Tan, Nicholas Opoku, Simon K Attah, Kwablah Awadzi, Annette C Kuesel, Janis Lazdins-Helds, Craig Rayner, Victoria Ryg-Cornejo, Mark Sullivan, Lawrence Fleckenstein
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 3, p e0010005 (2022)
BackgroundOnchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium. Moxidectin was approved
Externí odkaz:
https://doaj.org/article/26bf5cd03fd345daab3b326c25adf382
Autor:
Dennis Morrison, Sandip Roy, Craig Rayner, Ahmed Amer, Dan Howard, James R Smith, Thomas G Evans
Publikováno v:
PLoS ONE, Vol 2, Iss 12, p e1305 (2007)
The threat of potential pandemic influenza requires a reevaluation of licensed therapies for the prophylaxis or treatment of avian H5N1 infection that may adapt to man. Among the therapies considered for use in pandemic influenza is the co-administra
Externí odkaz:
https://doaj.org/article/1a7ec5bf3c1c4495a569fc8c17f82949
Autor:
Gilmar Reis, Lindsay Wilson, Dieter Ayers, Eduardo Silva, Daniela Medeiros, Lehana Thabane, Vitoria Campos, Thiago Ferreira, Castilho dos Santos, Ana Maria Nogueira, Ana Paula Almeida, Leonardo Savassi, Adhemar Neto, Ana Carolina Rocha, Carina Bitarães, Aline Milagres, Eduardo Callegari, Maria Simplicio, Luciene Ribeiro, Carla França, Rosemary Oliveira, Jamie Forrest, Ofir Harari, Hinda Ruton, Sheila Sprague, Paula McKay, Christina Guo, Josue Silva, Gordon Guyatt, Craig Rayner, Mark Dybul, Jeffrey S Glenn, Edward Mills
Approximately 20% of people infected with COVID-19 develop at least one persistent condition potentially attributable to their SARS-CoV-2 infection. We sought to determine the effectiveness of early COVID-19 treatment interventions on long COVID symp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f06b3cbb32c25eccb9d90065635aa266
https://doi.org/10.21203/rs.3.rs-2027075/v1
https://doi.org/10.21203/rs.3.rs-2027075/v1
Autor:
Michael Bettess, Simon Fisher, James S. Rush, Christopher Davis, Ian H. Frazer, Jonathan B. Baell, Michael P. Brown, Mark Sullivan, Michael P. Jennings, Michael A. McGuckin, Eloise Keeffe, Craig Rayner, Anand Gautam, Philip Kearney, C. Glenn Begley, Brett Carter, William N. Charman, Michael W. Parker, Mark R. Ashton, Brett Roberts, Angel F. Lopez, Darren J. Kelly
Publikováno v:
Science translational medicine. 13(612)
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fd4678be2e05d0047237accbbe9583
https://pubmed.ncbi.nlm.nih.gov/34550729
https://pubmed.ncbi.nlm.nih.gov/34550729